Abstract
Both prolymphocytic leukemia of T-cell (T-PLL) and B-cell (B-PLL) phenotype are rare and aggressive malignancies characterized by marked lymphocytosis and splenomegaly. Given the poor response to conventional therapy including alkylating agents or purine analogues, overall survival in most cases is less than 12 months. Monoclonal antibodies, e.g., rituximab in B-PLL and alemtuzumab in B-PLL and T-PLL, demonstrated encouraging activity in terms of response. However, long-term survival is rare, and allogeneic transplant might be considered as an option in selected patients.
Keywords
- Overall Survival
- Mantle Cell Lymphoma
- Autologous Stem Cell Transplantation
- Overall Response Rate
- Allogeneic Transplant
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Pathology: German Ott, Eric D. Hsi
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D (1997) Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 96(3):617–619
Campo E et al (2008) B-cell prolymphocytic leukaemia. In: Swerdlow SH et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon
Castagna L, Sarina B, Todisco E, Mazza R, Santoro A (2005) Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up. Bone Marrow Transplant 35(12):1225. doi:1704991 [pii];10.1038/sj.bmt.1704991 [doi]
Catovsky D (1982) Prolymphocytic leukaemia. Nouv Rev Fr Hematol 24(6):343–347
Chaar BT, Petruska PJ (2007) Complete response to alemtuzumab in a patient with B prolymphocytic leukemia. Am J Hematol 82(5):417. doi:10.1002/ajh.20843
Chow KU, Kim SZ, von Neuhoff N, Schlegelberger B, Stilgenbauer S, Wunderle L, Cordes HJ, Bergmann L (2011) Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. Eur J Haematol 87(5):426–433. doi:10.1111/j.1600-0609.2011.01680.x
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30(6):631–636. doi:10.1200/jco.2011.37.4223
Collins RH, Pineiro LA, Agura ED, Fay JW (1998) Treatment of T prolymphocytic leukemia with allogeneic bone marrow transplantation. Bone Marrow Transplant 21(6):627–628
Curtin NJ, Schwarer AP (2005) Nonmyeloablative peripheral blood stem cell transplant for T-cell prolymphocytic leukaemia complicated by fulminant haemolysis and acute renal failure at engraftment secondary to minor ABO incompatibility. Clin Lab Haematol 27(3):206–208
Davi F, Maloum K, Michel A, Pritsch O, Magnac C, Macintyre E, Salomon-Nguyen F, Binet JL, Dighiero G, Merle-Beral H (1996) High frequency of somatic mutations in the VH genes expressed in prolymphocytic leukemia. Blood 88(10):3953–3961
de Lavallade H, Faucher C, Furst S, El Cheikh J, Vey N, Coso D, Bouabdallah R, Stoppa AM, Gastaut JA, Blaise D, Mohty M (2006) Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission. Bone Marrow Transplant 37(7):709–710
Dearden C (2012) How I treat prolymphocytic leukemia. Blood 120(3):538–551. doi:blood-2012-01-380139 [pii];10.1182/blood-2012-01-380139 [doi]
Dearden CE, Matutes E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D (2001) High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98(6):1721–1726
Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D (2011) Alemtuzumab therapy in T-cell prolymphocytic leukaemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood 118(22):5799–5802
Del Giudice I, Davis Z, Matutes E, Osuji N, Parry-Jones N, Morilla A, Brito-Babapulle V, Oscier D, Catovsky D (2006) IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). Leukemia 20(7):1231–1237. doi:10.1038/sj.leu.2404238 [pii];
Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T (2012) BRAF inhibition in refractory hairy-cell leukemia. The New England journal of medicine 366(21):2038–2040.
Dunphy CH, Perkins SL (2001) Mantle cell leukemia, prolymphocytoid type: a rarely described form. Leuk Lymphoma 41(5–6):683–687
Dyer MJ, Hale G, Hayhoe FG, Waldmann H (1989) Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73(6):1431–1439
Galton DA, Goldman JM, Wiltshaw E, Catovsky D, Henry K, Goldenberg GJ (1974) Prolymphocytic leukaemia. Br J Haematol 27(1):7–23
Garand R, Goasguen J, Brizard A, Buisine J, Charpentier A, Claisse JF, Duchayne E, Lagrange M, Segonds C, Troussard X, Flandrin G (1998) Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Francais d’Hematologie Cellulaire. Br J Haematol 103(2):488–494
Garderet L, Bittencourt H, Kaliski A, Daniel M, Ribaud P, Socie G, Gluckman E (2001) Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation. Eur J Haematol 66(2):137–139
Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 22(2):185–191
Greenwood J, Clark M, Waldmann H (1993) Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 23(5):1098–1104
Hale G, Rebello P, Brettman LR, Fegan C, Kennedy B, Kimby E, Leach M, Lundin J, Mellstedt H, Moreton P, Rawstron AC, Waldmann H, Osterborg A, Hillmen P (2004) Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104(4):948–955
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164–1174. doi:S0140-6736(10)61381-5 [pii];10.1016/S0140-6736(10)61381-5 [doi]
Heit W, Bunjes D, Wiesneth M, Schmeiser T, Arnold R, Hale G, Waldmann H, Heimpel H (1986) Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. Br J Haematol 64(3):479–486
Hercher C, Robain M, Davi F, Garand R, Flandrin G, Valensi F, Vandeputte H, Albert A, Maynadie M, Troussard X, Simon GH, Lespinasse J, Portefaix G, Merle-Beral H (2001) A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma 42(5):981–987
Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D (2004) A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 104(2):328–335
Herling M, Patel KA, Teitell MA, Konopleva M, Ravandi F, Kobayashi R, Jones D (2008) High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 111(1):328–337
Herold M, Spohn C, Schlag R et al (2003) Fludarabine/cyclophosphamide chemotherapy for B – prolymphocytic leukaemia. Blood 102(abstract):2499
Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson G, Stilgenbauer S, Dohner H, Kandler G, Eichhorst B, Hallek M, Herling M (2013) Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer. doi:10.1002/cncr.27972
Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz MM, Arora M (2010) Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biology of Blood and Marrow Transplant 16(4):543–547
Keating MJ, Cazin B, Coutre S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjonnfjord G, Bekradda M, Itzhaki M, Herait P (2002) Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 20(1):205–213
Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, Ketterer N, Catovsky D, Ethell M, Matutes E, Dearden CE (2010) Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol 149(6):907–910
Kruspe RC, Ashraf KK, Foran JM, Salzman DE, Reddy VV, Vaughan WP (2007) Successful treatment of T-cell prolymphocytic leukemia with full-intensity conditioning followed by matched unrelated donor allogeneic stem cell transplantation. Clin Adv Hematol Oncol 5(11):882–884
Lampert I, Catovsky D, Marsh GW, Child JA, Galton DA (1980) The histopathology of prolymphocytic leukaemia with particular reference to the spleen: a comparison with chronic lymphocytic leukaemia. Histopathology 4(1):3–19
Langabeer SE, Quinn F, O’Brien D, McElligott AM, Kelly J, Browne PV, Vandenberghe E (2012) Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia. Leuk Res 36(4):483–484. doi:0145-2126(11)00606-0 [pii];10.1016/j.leukres.2011.12.015 [doi]
Lennert KFA (1992) Histopathology of non-Hodgkin’s lymphomas, 2nd edn. Springer, New York
Lens D, Matutes E, Catovsky D, Coignet LJ (2000) Frequent deletions at 11q23 and 13q14 in B cell prolymphocytic leukemia (B-PLL). Leukemia 14(3):427–430
Matutes E (1998) T-cell prolymphocytic leukemia. Cancer Control 5(1):19–24
Matutes E (2012) Novel and emerging drugs for rarer chronic lymphoid leukaemias. Curr Cancer Drug Targets 12(5):484–504. doi:CCDT-EPUB-20120403-004 [pii]
Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C, Sempere A, Catovsky D (1991) Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78(12):3269–3274
Matutes E, Wotherspoon A, Catovsky D (2003) The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 16(1):41–56
Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D (1994) The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 12(12):2588–2593
Mourad YA, Taher A, Chehal A, Shamseddine A (2004) Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody. Ann Hematol 83(5):319–321. doi:10.1007/s00277-003-0805-z
Murase K, Matsunaga T, Sato T, Kuribayashi K, Kogawa K, Kawano Y, Okamoto T, Takayama T, Watanabe H, Niitsu Y, Hirayama Y (2003) Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement. Int J Clin Oncol 8(6):391–394
Nowak D, Le Toriellec E, Stern MH, Kawamata N, Akagi T, Dyer MJ, Hofmann WK, Ogawa S, Koeffler HP (2009) Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. Haematologica 94(4):518–527
O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29(9):1182–1189. doi:JCO.2010.29.9024 [pii];10.1200/JCO.2010.29.9024 [doi]
Okamura K, Ikeda T, Shimakura Y, Yoshiba F, Kishi K, Ando K, Hotta T (2005) Allogeneic bone marrow transplantation for chemotherapy-resistant T-prolymphocytic leukemia. Rinsho Ketsueki 46(7):527–531
Osuji N, Matutes E, Catovsky D, Lampert I, Wotherspoon A (2005) Histopathology of the spleen in T-cell large granular lymphocyte leukemia and T-cell prolymphocytic leukemia: a comparative review. Am J Surg Pathol 29(7):935–941
Ozpuyan F, Meyer P, Ni H, Al Masri H, Alkan S (2007) Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL). Leuk Lymphoma 48(11):2247–2250
Pamuk GE, Puyan FO, Unlu E, Ozturk E, Demir M (2009) The first case of de novo B-cell prolymphocytic leukemia with central nervous system involvement: description of an unreported complication. Leuk Res 33(6):864–867. doi:S0145-2126(08)00393-7 [pii];10.1016/j.leukres.2008.09.013 [doi]
Pawson R, Dyer MJ, Barge R, Matutes E, Thornton PD, Emmett E, Kluin-Nelemans JC, Fibbe WE, Willemze R, Catovsky D (1997) Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 15(7):2667–2672
Pekarsky Y, Hallas C, Isobe M, Russo G, Croce CM (1999) Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. Proc Natl Acad Sci USA 96(6):2949–2951
Put N, Van RK, Konings P, Meeus P, Brusselmans C, Rack K, Gervais C, Nguyen-Khac F, Chapiro E, Radford-Weiss I, Struski S, Dastugue N, Gachard N, Lefebvre C, Barin C, Eclache V, Fert-Ferrer S, Laibe S, Mozziconacci MJ, Quilichini B, Poirel HA, Wlodarska I, Hagemeijer A, Moreau Y, Vandenberghe P, Michaux L (2012) Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. Ann Hematol 91(6):863–873. doi:10.1007/s00277-011-1393-y
Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H (2009) Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 27(32):5425–5430
Rondelli D, Lauria F, Zinzani PL, Raspadori D, Ventura MA, Galieni P, Birtolo S, Forconi F, Algeri R, Tura S (1997) 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. Eur J Haematol 58(1):46–50
Rowan W, Tite J, Topley P, Brett SJ (1998) Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 95(3):427–436
Ruchlemer R, Parry-Jones N, Brito-Babapulle V, Attolico I, Wotherspoon AC, Matutes E, Catovsky D (2004) B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia. Br J Haematol 125(3):330–336
Saven A, Lee T, Schlutz M, Jacobs A, Ellison D, Longmire R, Piro L (1997) Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. J Clin Oncol 15(1):37–43
Shvidel L, Shtalrid M, Bassous L, Klepfish A, Vorst E, Berrebi A (1999) B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk Lymphoma 33(1–2):169–179. doi:10.3109/10428199909093739
Shvidel L, Shtalrid M, Klepfish A, Haran M, Berrebi A (2000) Successful autologous stem cell transplantation in aggressive prolymphocytic leukemia. Am J Hematol 63(4):230–231. doi:10.1002/(SICI)1096-8652(200004)63:4%3C230::AID-AJH12%3E3.0.CO;2-5 [pii]
Sibbald R, Catovsky D (1979) Complete remission in prolymphocytic leukaemia with the combination chemotherapy–-CHOP. Br J Haematol 42(3):488–490
Singleton TP, Anderson MM, Ross CW, Schnitzer B (1999) Leukemic phase of mantle cell lymphoma, blastoid variant. Am J Clin Pathol 111(4):495–500
Soma L, Cornfield DB, Prager D, Nowell P, Bagg A (2002) Unusually indolent T-cell prolymphocytic leukemia associated with a complex karyotype: is this T-cell chronic lymphocytic leukemia? Am J Hematol 71(3):224–226
Stern MH, Soulier J, Rosenzwajg M, Nakahara K, Canki-Klain N, Aurias A, Sigaux F, Kirsch IR (1993) MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene 8(9):2475–2483
Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, Bar-Shira A, James MR, Lichter P, Dohner H (1997) Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 3(10):1155–1159
Stilgenbauer S, Zenz T, Winkler D, Buhler A, Schlenk RF, Groner S, Busch R, Hensel M, Duhrsen U, Finke J, Dreger P, Jager U, Lengfelder E, Hohloch K, Soling U, Schlag R, Kneba M, Hallek M, Dohner H (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27(24):3994–4001
Swerdlow SH, Campo E, Harris NL et al (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
Tanimoto TE, Hirano A, Nagafuji K, Yamasaki S, Hashiguchi M, Okamura T, Kamezaki K, Takase K, Numata A, Miyamoto T, Fukuda T, Harada M (2005) Mismatched unrelated cord blood transplantation in a patient with T-cell prolymphocytic leukemia. Leukemia 19(4):679–681
Vartholomatos G, Tsiara S, Christou L, Panteli A, Kaiafas P, Bourantas KL (1999) Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia. Acta Haematol 102(2):94–98. doi:40977 [pii]
Viswanatha DS et al (2012) Mature B cell neoplasms: chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, and lymphoplasmocytic leukemia. In: Jaffe ES et al (eds) Hematopathology. Elsevier, Philadelphia
Weide R, Pandorf A, Heymanns J, Koppler H (2004) Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 45(12):2445–2449. doi:TGAY99TY8R1N4B44 [pii];10.1080/10428190400004521 [doi]
Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T (2010) The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 116(22):4578–4587
Wiktor-Jedrzejczak W, Dearden C, de Wreede L, van Biezen A, Brinch L, Leblond V, Brune M, Volin L, Kazmi M, Nagler A, Schetelig J, de Witte T, Dreger P (2012) Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia 26(5):972–976
Wong KF, So CC, Chan JK (2002) Nucleolated variant of mantle cell lymphoma with leukemic manifestations mimicking prolymphocytic leukemia. Am J Clin Pathol 117(2):246–251
Yong HX, Linn YC, Ong KH, Tan D (2012) Chemoimmunotherapy with bendamustine hydrochloride and alemtuzumab demonstrates synergism in T-prolymphocytic leukemia. Leuk Res 36(8):e163–e165
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ott, G., Hsi, E.D., Seymour, J.F., Hopfinger, G. (2014). B-Cell Prolymphocytic Leukemia (B-PLL) and T-Cell Prolymphocytic Leukemia (T-PLL). In: Dreyling, M., Williams, M. (eds) Rare Lymphomas. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39590-1_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-39590-1_17
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-39589-5
Online ISBN: 978-3-642-39590-1
eBook Packages: MedicineMedicine (R0)